title: Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile.
abstract: Long-term use of cyclosporine after renal transplantation results in nephrotoxicity and an increased cardiovascular risk profile. Tacrolimus may be more favorable in this respect. In this randomized controlled study in 124 renal transplant patients, the effects of conversion from cyclosporine to tacrolimus on renal function, cardiovascular risk factors, and perceived side-effects were investigated after a follow-up of 2 years. After conversion from cyclosporine to tacrolimus renal function remained stable, whereas continuation of cyclosporine was accompanied by a rise in serum creatinine from 142 +/- 48 micromol/L to 157 +/- 62 micromol/L (p < 0.05 comparing both groups). Conversion to tacrolimus resulted in a sustained reduction in systolic and diastolic blood pressure, and a sustained improvement in the serum lipid profile, leading to a reduction in the Framingham risk score from 5.7 +/- 4.3 to 4.8 +/- 5.3 (p < 0.05). Finally, conversion to tacrolimus resulted in decreased scores for occurrence of and distress due to side-effects. In conclusion, conversion from cyclosporine to tacrolimus in stable renal transplant patients is beneficial with respect to renal function, cardiovascular risk profile, and side-effects. Therefore, for most renal transplant patients tacrolimus will be the drug of choice when long-term treatment with a calcineurin inhibitor is indicated.
authors.affiliation: Department of Nephrology, University Medical Centre of Nijmegen, the Netherlands. m.artz@nier.umcn.nl
authors.forename: Marika A
authors.initials: MA
authors.lastname: Artz
authors.forename: Johannes M M
authors.initials: JM
authors.lastname: Boots
authors.forename: Gerry
authors.initials: G
authors.lastname: Ligtenberg
authors.forename: Joke I
authors.initials: JI
authors.lastname: Roodnat
authors.forename: Maarten H L
authors.initials: MH
authors.lastname: Christiaans
authors.forename: Pieter F
authors.initials: PF
authors.lastname: Vos
authors.forename: Philip
authors.initials: P
authors.lastname: Moons
authors.forename: George
authors.initials: G
authors.lastname: Borm
authors.forename: Luuk B
authors.initials: LB
authors.lastname: Hilbrands
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000502:physiology*; D008055:Lipids / Q000097:blood; D011446:Prospective Studies; D011788:Quality of Life; D012307:Risk Factors; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007166:Immunosuppressive Agents; D008055:Lipids; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus